Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
MDGL Stock Price Chart Interactive Chart >
MDGL Price/Volume Stats
|Current price||$112.12||52-week high||$137.28|
|Prev. close||$114.35||52-week low||$56.82|
|Day high||$115.39||Avg. volume||210,275|
|50-day MA||$116.44||Dividend yield||N/A|
|200-day MA||$115.36||Market Cap||1.80B|
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
MDGL Latest News Stream
|Loading, please wait...|
MDGL Latest Social Stream
View Full MDGL Social Stream
Latest MDGL News From Around the Web
Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) based on that […]
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
* Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET. * In the 100 mg open label arm of MAESTRO-NAFLD: * At week 16, MRI-PDFF (magnetic resonance imaging-proton density fat fraction) reduction compared to baseline was 53% overall (p<0.0001) and up to 62% in key subgroups * At weeks 12-24, statistically significant lowering of liver enzymes, inflammatory biomarkers and atherogenic lipids and lipoproteins were observed * At week 16, compared to baseline, a meaningful reduction (p=0.003) in magnetic resonance elastography (MRE), a measure of liver of fibrosis and inflammation was seenCONSHOHOCKEN, P...
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights - Stocks News Feed
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. The original target enrollment for MAESTRO… Read More »Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
MDGL Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!